NewGenIvf Group Limited (NIVFW) 股票分析

公司概述

NewGenIvf Group Limited operates as an investment holding company primarily focused on delivering assisted reproductive services to couples and individuals seeking fertility treatments across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a comprehensive range of fertility treatment solutions, including in vitro fertilization, positioning it within the specialized healthcare and biotechnology service landscape. Regarding its scale, the company reports a trailing twelve-month revenue of $4.73 million and maintains a price-to-book ratio of 0.00, while specific metrics such as market capitalization and employee count are not currently disclosed in available data. The reported revenue of $4.73 million indicates a niche operational footprint that serves a targeted demographic, suggesting the business derives significant value from high-margin procedural services rather than mass-market volume. The absence of disclosed market cap data implies that valuation is currently driven by asset backing or specific growth potential rather than broad market trading volume, while the undisclosed employee count prevents a direct assessment of labor intensity relative to revenue generation.

财务健康

The company's financial performance for the trailing twelve months demonstrates a revenue of $4.73 million alongside a net income of $9.88 million, which contrasts sharply with an EBITDA of $-10,538,352. This divergence between net income and EBITDA reveals a cost structure where non-operating expenses or significant one-time charges likely inflate reported profitability compared to core operational cash generation. Free cash flow stands at $-11,179,275, indicating that the company is currently burning cash, which limits its financial flexibility for capital expenditures or organic expansion without external financing. Margin analysis highlights a gross margin of 20.2%, reflecting moderate profitability on individual services, while the operating margin of -349.1% and profit margin of 209.0% suggest substantial non-operating losses or gains that distort the view of operational efficiency. On the balance sheet, cash holdings of $1.30 million are outweighed by total debt of $4.87 million, resulting in a debt-to-equity ratio of 18.74, which characterizes a highly leveraged position reliant on equity rather than creditor financing. Liquidity is supported by a current ratio of 3.12, indicating that the company holds sufficient current assets to cover short-term obligations more than three times over, providing a buffer despite the negative operating cash flow. Return on equity is reported at 79.4%, while return on assets is -36.9%, a disparity that suggests the company is utilizing shareholder equity efficiently to generate returns, even as the broader asset base incurs losses, potentially due to the specific accounting treatment of its intangible or long-term assets.

估值评估

Valuation multiples for NewGenIvf Group Limited show a trailing P/E ratio of N/A and a forward P/E ratio of N/A, a situation where the absence of data prevents a direct comparison of expected earnings trajectory against historical performance. The price-to-book ratio is stated as 0.00, indicating that the market capitalization effectively trades at zero times book value, which may reflect a distressed valuation or specific accounting adjustments regarding the company's asset base. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also listed as N/A, suggesting that traditional valuation models are not currently applicable due to the company's specific financial structure or lack of trading data. The stock's 52-week high and low are both recorded at $0.02, meaning the current price sits exactly at the midpoint of this extremely narrow trading range with no deviation. The beta value is listed as N/A, which implies that there is insufficient data to quantify the stock's price volatility relative to the broader market movements.

Growth & Income

Revenue growth year-over-year is recorded at 11.9%, whereas earnings growth year-over-year is listed as N/A, preventing a direct comparison of whether earnings are expanding faster or slower than top-line sales. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is N/A, meaning the entity reinvests its earnings or retains capital for operations rather than distributing income to shareholders. The absence of dividend payments suggests a growth-oriented capital allocation strategy where cash is prioritized for sustaining operations or paying down the existing $4.87 million in debt rather than providing regular income streams. Overall, the company presents a profile characterized by positive revenue expansion in the fertility services sector but faces challenges in converting that revenue into sustainable operational cash flow and maintaining a positive EBITDA position.